Ayasa Fujibayashi

Ayasa Fujibayashi

Auto-generated profile, based on publicly available information

Ayasa Fujibayashi

Department of Pharmacy, Gifu University Hospital, Gifu, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
TNTakashi Niwa
Takashi Niwa
JYJun Yonetamari
Jun Yonetamari
NHNozomi Hayama
Nozomi Hayama
AFAyasa Fujibayashi
Ayasa Fujibayashi
SISyuri Ito‐Takeichi
Syuri Ito‐Takeichi
NMNobuo Murakami
Nobuo Murakami

5 February 2019 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SISyuri Ito‐Takeichi
Syuri Ito‐Takeichi
TNTakashi Niwa
Takashi Niwa
AFAyasa Fujibayashi
Ayasa Fujibayashi
KSKeiko Suzuki
Keiko Suzuki
HOHirotoshi Ohta
Hirotoshi Ohta
YIYoshinori Itoh
Yoshinori Itoh
What is known and objective Implementation of an antifungal stewardship programme is a recognized need. However, there is insufficient information to confirm the impact of antifungal stewardship interventions. Further, few studies have evaluated the clinical effects of an antifungal stewardship intervention using 1‐3, β‐D‐glucan (βDG) testing. The aim of the present study was to evaluate the impact of implementing an antifungal stewardship with monitoring of βDG values on antifungal use and clinical outcomes. Methods A single institutional prospective cohort study was conducted to evaluate the impact of implementing daily reviews of antifungal agents and monitoring patients who measured βDG values since August 2013. Antifungal consumption and clinical outcomes in patients with Candida bloodstream infection were compared before and after the intervention. Results After implementation of the programme, parental antifungal use was significantly reduced compared to that before intervention (P = 0.006). In the after‐intervention group, the rate of 60‐day clinical failure in patients with Candida bloodstream infection was significantly reduced, from 80.0% (28/35) to 36.4% (8/22) (P < 0.001), and the rate of 60‐day mortality associated with Candida bloodstream infection tended to be reduced, from 42.9% (15/35) to 18.2% (4/22) (P = 0.081) compared to the before‐intervention group. The incidence of adverse events associated with antifungal agents was significantly lower in the after‐intervention group than in the before‐intervention group (51.4% [18/35] vs 13.6% [3/22], P = 0.004). What is new and conclusion Our findings suggest that daily review of the use of antifungal agents and monitoring of measured βDG values was highly effective in reducing antifungal consumption and improving the clinical outcomes of patients with Candida bloodstream infection.

4 January 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SHSaki Harada
Saki Harada
TNTakashi Niwa
Takashi Niwa
YHYusuke Hoshino
Yusuke Hoshino
AFAyasa Fujibayashi
Ayasa Fujibayashi
ASAkio Suzuki
Akio Suzuki

27 September 2018 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
AFAyasa Fujibayashi
Ayasa Fujibayashi
TNTakashi Niwa
Takashi Niwa
STSyuri Takeichi
Syuri Takeichi
KSKeiko Suzuki
Keiko Suzuki
HOHirotoshi Ohta
Hirotoshi Ohta
YIYoshinori Itoh
Yoshinori Itoh
Background Antimicrobial stewardship is required to ensure the appropriate use of antimicrobials. However, few reports have shown the impact of antimicrobial stewardship on clinical outcomes. Methods To evaluate the clinical outcomes of implementing a prospective audit with intervention and feedback without carbapenem pre‐authorisation, we conducted a single‐centre, prospective cohort study in patients who received carbapenem injection. Subjects were allocated to groups receiving antimicrobial agents before (non‐intervention group) or after (intervention group) the implementation of an antimicrobial stewardship programme in the clinical setting. Results The intervention facilitated the rate of choice of effective antimicrobials on day 2 from the onset of infection (from 63.2% to 90.2%; P < 0.001). Moreover, the rates of clinical failure‐free survival (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.47‐0.89; P = 0.008) and re‐infection‐free survival (HR, 0.35; 95% CI, 0.18‐0.68; P = 0.002) were significantly higher in the intervention group than in the non‐intervention group. A multivariate Cox proportional hazard analysis indicated that non‐implementation of antimicrobial stewardship was a significant risk factor for clinical failure in patients receiving carbapenem injection (HR, 1.56; 95% CI, 1.11‐2.19; P = 0.010). Conclusions Our prospective audit with intervention and feedback strategy without carbapenem restriction facilitated the choice of optimal antimicrobials at an early stage of infection and improved clinical outcomes in patients who received carbapenem.

5 November 2018 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
AFAyasa Fujibayashi
Ayasa Fujibayashi
TNTakashi Niwa
Takashi Niwa
MTMayumi Tsuchiya
Mayumi Tsuchiya
STSyuri Takeichi
Syuri Takeichi
KSKeiko Suzuki
Keiko Suzuki
NMNobuo Murakami
Nobuo Murakami
Background The standard duration of administration of antimicrobial prophylaxis in surgery and non‐surgical invasive therapy was shortened according to the promotion of appropriate use. Here, we conducted an intervention to optimize antimicrobial prophylaxis by revising all relevant clinical pathways based on the most recent guidelines. Methods We conducted a single‐center, prospective cohort study in patients who received antimicrobial prophylaxis to evaluate outcomes following revision of the clinical pathways for antimicrobial prophylaxis. Antibiotic consumption and the duration of antibiotic administration were compared before and after revising the clinical pathways. Results Thirty‐five of 171 clinical pathways were considered inappropriate for antimicrobial use and were optimized. After this revision, the duration of antibiotic administration was significantly shortened (before revision: 3 [1–5] days vs after revision: 2 [1–3] days, median [interquartile range], P<0.001). The rate of discontinuation of antibiotics within 48 h after surgery or non‐surgical invasive therapy was significantly higher after the revision (62.4% vs 79.2%, P<0.001). In contrast, the incidence of surgical site infection was not significantly different before and after the revision (5.8% vs 4.4%, P=0.177). A multivariate Cox proportional analysis indicated that revision of the clinical pathways was one of the prognostic factors associated with the discontinuation of antibiotics within 48 h after surgery or non‐surgical invasive therapy (hazard ratio, 0.69; 95% confidence interval, 0.63–0.76, P<0.001). Conclusions Our findings suggest that revising all relevant clinical pathways was highly effective in reducing antibiotic consumption and shortening the antibiotic administration period without increasing the incidence of surgical site infections.